Viral Vector and Plasmid DNA Manufacturing Market, by Product Type (Viral Vector, Plasmid DNA, and Nonviral Vector), by Application (Cancer, Inherited disease, Viral Infection, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
- Report code : CMI1962 |
- Industry :
Biotechnology
- Published On : Feb 2019 |
- Pages : 169 Pages |
- Format :
Global Viral Vector and Plasmid DNA Manufacturing Market – Novel Approach for Disease Management
Viral vector and plasmid DNA manufacturing plays a major role in modern healthcare, as it reduces disease management price by generating a wider range of immune response types and supporting to decrease the periodic medication dosage.
The global viral vector and plasmid DNA manufacturing market size was valued at US$ 290.0 million in 2017, and is expected to exhibit a CAGR of 22.5% over the forecast period (2018 – 2026).
Figure 1. Global Viral Vector and Plasmid DNA Manufacturing Market Value (US$ Mn), by Region, 2017
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of cancer and inherited disorders is expected to propel growth of the viral vector and plasmid DNA manufacturing market
Viral vector and plasmid DNA manufacturing is used in application of gene therapy to diagnose and treat diseases in patients. High prevalence of cancer is expected to propel demand for gene therapy, which in turn is expected to drive the market growth. According to World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012, and was responsible for 8.8 million deaths worldwide in 2015. Moreover, WHO stated that, the number of new cases of cancer is expected to rise by around 70% by the end of 2030.
Similarly, according to the International Quarterly Journal of Research in Ayurveda, published in 2010, estimated around 20 – 30% of all infant deaths are due to genetic disorders, and around 11.1% of pediatric hospital admissions are for children with inherited disorders.
Furthermore, rising awareness regarding gene therapy is propelling growth of the viral vector and plasmid DNA manufacturing market over the forecast period. For instance, in November 2018, the National Institutes of Health (NIH) launched a new initiative to accelerate adoption of gene therapy to cure around 20 million patients diagnosed with sickle cell disease.
However, complications such as risk of mutagenesis, safety and efficacy issues, and stringent regulatory framework are expected to limit the adoption of gene therapy, thereby hindering the market growth.
Figure 2. Global Viral Vector and Plasmid DNA Manufacturing Market Share (%), by Design, 2018 and 2026
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of viral infection in North America is expected to bolster the market growth
North America holds a dominant position in the global viral vector and plasmid DNA manufacturing market, owing to high prevalence of viral infection in the region. According to the National Center for Biotechnology Information (NCBI) report, published in December 2017, around 98 cases diagnosed with Powassan Virus were reported from 1999 to 2016, with an increase of 671% cases from 1999 to 2016.
Moreover, increasing research and development activities in the field of viral vector and plasmid DNA manufacturing is expected to enhance its demand in the near future. For instance, in April 2017, Transgene announced plans for a new clinical research collaboration of investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) with standard chemotherapy (CT) as a first-line treatment for advanced non-squamous, non-small cell lung cancer (NSCLC) in patients, which is under Phase 2 clinical trial.
Key Players
Major players operating in the global viral vector and plasmid DNA manufacturing market include, Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene SA, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure, MassBiologics, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.
Viral vector and plasmid DNA is product of gene therapy, which is used in diagnosis and treatment of diseases such as cancer, inherited diseases, viral infections, and others. The therapeutic DNA is introduced in host with the help of a vector. Adeno associated virus based vector are much safer as compared with others viral vectors due to its integration at same site in human genome, and has wide application in various disorders such as Alzheimer’s disease.
Market Dynamics
Increasing prevalence of cancer is a major factor driving growth of the viral vector and plasmid DNA manufacturing market. According to World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, government and other organizations’ initiatives regarding awareness of gene is expected to boost growth of the market. For instance, in June 2018 Alliance for Regenerative Medicine launched ARM Foundation for Cell and Gene Medicine to educate, empower, and engage public about cell and gene medicine as a treatment option. The foundation will accelerate patient’s access to safe and curative gene therapies.
However, safety and efficacy issues, stringent regulatory framework and risk of mutagenesis are expected to limit the adoption if gene therapy, thereby hindering the market growth. For instance, some viral vectors, such as gamma-retroviruses, insert its genomes at random location on the host chromosomes, which can lead to cancer.
Key features of the study:
- This report provides in-depth analysis of the viral vector and plasmid DNA manufacturing market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene SA, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, uniQure MassBiologics, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the viral vector and plasmid DNA manufacturing market
Detailed Segmentation:
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:
- Viral Vector
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Nonviral Vector
- Viral Vector
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Application:
- Cancer
- Inherited Disorder
- Viral Infection
- Others
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Geography:
- North America
- By Product Type:
- Viral Vector
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Nonviral Vector
- Viral Vector
- By Application:
- Cancer
- Inherited Disorder
- Viral Infection
- Others
- By Country:
- U.S.
- Canada
- By Product Type:
- Latin America
- By Product Type:
- Viral Vector
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Nonviral Vector
- Viral Vector
- By Application:
- Cancer
- Inherited Disorder
- Viral Infection
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Europe
- By Product Type:
- Viral Vector
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Nonviral Vector
- Viral Vector
- By Application:
- Cancer
- Inherited Disorder
- Viral Infection
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Product Type:
- Asia Pacific
- By Product Type:
- Viral Vector
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Nonviral Vector
- Viral Vector
- By Application:
- Cancer
- Inherited Disorder
- Viral Infection
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Product Type:
- Middle East
- By Product Type:
- Viral Vector
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Nonviral Vector
- Viral Vector
- By Application:
- Cancer
- Inherited Disorder
- Viral Infection
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Africa
- By Product Type:
- Viral Vector
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Nonviral Vector
- Viral Vector
- By Application:
- Cancer
- Inherited Disorder
- Viral Infection
- Others
- By Country:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- North America
- Company Profiles
- Kaneka Eurogentec S.A.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- FinVector
- Brammer Bio
- Cell and Gene Therapy Catapult
- Transgene SA
- FUJIFILM Diosynth Biotechnologies
- Sanofi
- Spark Therapeutics
- Cobra Biologics
- uniQure
- MassBiologics
- 4D Molecular Therapeutics
- Renova Therapeutics
- Shenzhen SiBiono GeneTech Co., Ltd.
- Thermo Fisher Scientific, Inc.
- Kaneka Eurogentec S.A.*
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Challenges Faced By Rare Disease Drug Discovery Programs
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- Regulatory Scenario
- Comparative Analysis Of Different Types Of Viral Systems
- Collaborations And Agreements
- New Product Launches
- Investment Opportunities
- Strategies For Product Development And Application Pathways
- Brand Analysis
- Cell & Gene Therapy Manufacturing Capacities In Europe
- Market Dynamics
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2018 – 2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Viral Vector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Retroviral
- Adenoviral
- Lentiviral
- Adeno Associated
- Others
- Plasmid DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Nonviral Vector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Application, 2018 – 2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Inherited Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Viral Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2018 – 2026, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Kaneka Eurogentec S.A.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- FinVector
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Brammer Bio
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cell and Gene Therapy Catapult
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Transgene SA
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- FUJIFILM Diosynth Biotechnologies
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Spark Therapeutics
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cobra Biologics
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- uniQure
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- MassBiologics
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- 4D Molecular Therapeutics
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Renova Therapeutics
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Shenzhen SiBiono GeneTech Co., Ltd.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Thermo Fisher Scientific, Inc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Kaneka Eurogentec S.A.
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 25 market data tables and 27 figures on "Viral Vector and Plasmid DNA Manufacturing Market - Global forecast to 2026".
Related Insights :
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.